- Home
- CYBR vs TEVA Comparison
CYBR vs TEVA Comparison
Compare CYBR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBR
- TEVA
- Stock Information
- Founded
- CYBR 1999
- TEVA 1901
- Country
- CYBR Israel
- TEVA Israel
- Employees
- CYBR N/A
- TEVA N/A
- Industry
- CYBR Computer Software: Prepackaged Software
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- CYBR Technology
- TEVA Health Care
- Exchange
- CYBR Nasdaq
- TEVA Nasdaq
- Market Cap
- CYBR 24.0B
- TEVA 21.2B
- IPO Year
- CYBR 2014
- TEVA N/A
- Fundamental
- Price
- CYBR $516.20
- TEVA $25.17
- Analyst Decision
- CYBR Buy
- TEVA Strong Buy
- Analyst Count
- CYBR 32
- TEVA 7
- Target Price
- CYBR $449.22
- TEVA $25.86
- AVG Volume (30 Days)
- CYBR 458.5K
- TEVA 12.7M
- Earning Date
- CYBR 11-06-2025
- TEVA 11-05-2025
- Dividend Yield
- CYBR N/A
- TEVA N/A
- EPS Growth
- CYBR N/A
- TEVA N/A
- EPS
- CYBR N/A
- TEVA 0.62
- Revenue
- CYBR $1,302,851,000.00
- TEVA $16,776,000,000.00
- Revenue This Year
- CYBR $35.70
- TEVA $4.11
- Revenue Next Year
- CYBR $19.22
- TEVA $0.40
- P/E Ratio
- CYBR N/A
- TEVA $39.31
- Revenue Growth
- CYBR 43.26
- TEVA 0.02
- 52 Week Low
- CYBR $288.00
- TEVA $12.47
- 52 Week High
- CYBR $526.19
- TEVA $25.35
- Technical
- Relative Strength Index (RSI)
- CYBR 59.57
- TEVA 80.04
- Support Level
- CYBR $493.67
- TEVA $23.61
- Resistance Level
- CYBR $522.87
- TEVA $25.00
- Average True Range (ATR)
- CYBR 8.57
- TEVA 0.76
- MACD
- CYBR -1.46
- TEVA 0.53
- Stochastic Oscillator
- CYBR 71.70
- TEVA 96.62
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.